ArticleAdvances in therapy2026
Healthcare Utilization and Costs in People Living with HIV and Neuropsychiatric Disorders in the United States.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeople living with HIV (PLWH) face an increased prevalence and risk of neuropsychiatric disorders than individuals without HIV. This study compared incremental all-cause healthcare resource utilization (HCRU) and costs among US antiretroviral therapy (ART)-treated PLWH with versus without neuropsychiatric disorders.
methodsA retrospective claims analysis was conducted using Optum's de-identified Clinformatics
resultsAmong 22,402 PLWH, 9506 (42.4%) had neuropsychiatric disorders. PLWH with versus without neuropsychiatric disorders were older (mean age 56 vs. 54 years), more often female (21.0% vs. 17.5%), white (51.0% vs. 44.0%), had higher comorbidity (mean Quan-Charlson 1.82 vs. 0.92), and baseline total costs ($4579 vs. $3416); all P < 0.001. Unadjusted all-cause PPPM HCRU and costs were significantly higher among PLWH with neuropsychiatric disorders than among those without; all P < 0.001. PLWH with neuropsychiatric disorders generally had higher adjusted all-cause PPPM HCRU (including 28% more office visits) and higher total costs; outpatient emergency department and outpatient other visit and costs were not significantly different.
conclusionsPLWH with neuropsychiatric disorders have higher all-cause HCRU and costs than those without these conditions. Further research on the role of HIV and ART in the development of neuropsychiatric disorders may support more individualized care and help reduce excess HCRU and costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.